Michael Michael1, Winston Liauw2, Sue-Anne McLachlan3, Emma Link4, Annetta Matera4, Michael Thompson5, Michael Jefford6, Rod J Hicks5, Carleen Cullinane7, Athena Hatzimihalis7, Ian G Campbell8, Simone Rowley8, Phillip J Beale9, Christos S Karapetis10, Timothy Price11, Mathew E Burge12. 1. Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia. Michael.Michael@petermac.org. 2. Department of Medical Oncology, St. George's Hospital, Sydney, Australia. 3. Department of Medical Oncology, St. Vincent's Hospital, Melbourne, Australia. 4. Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia. 5. Division of Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia. 6. Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia. 7. Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia. 8. Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia. 9. Department of Medical Oncology, Royal Prince Alfred Hospital, Sydney, Australia. 10. Department of Medical Oncology, Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Adelaide, Australia. 11. Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, Australia. 12. Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Abstract
PURPOSE: Irinotecan (IR) displays significant PK/PD variability. This study evaluated functional hepatic imaging (HNI) and extensive pharmacogenomics (PGs) to explore associations with IR PK and PD (toxicity and response). METHODS: Eligible patients (pts) suitable for Irinotecan-based therapy. At baseline: (i) PGs: blood analyzed by the Affymetrix-DMET™-Plus-Array (1936 variants: 1931 single nucleotide polymorphisms [SNPs] and 5 copy number variants in 225 genes, including 47 phase I, 80 phase II enzymes, and membrane transporters) and Sanger sequencing (variants in HNF1A, Topo-1, XRCC1, PARP1, TDP, CDC45L, NKFB1, and MTHFR), (ii) HNI: pts given IV 250 MBq-99mTc-IDA, data derived for hepatic extraction/excretion parameters (CLHNI, T1/2-HNI, 1hRET, HEF, Td1/2). In cycle 1, blood was taken for IR analysis and PK parameters were derived by non-compartmental methods. Associations were evaluated between HNI and PGs, with IR PK, toxicity, objective response rate (ORR) and progression-free survival (PFS). RESULTS: N = 31 pts. The two most significant associations between PK and PD with gene variants or HNI parameters (P < 0.05) included: (1) PK: SN38-Metabolic Ratio with CLHNI, 1hRET, (2) Grade 3+ diarrhea with SLC22A2 (rs 316019), GSTM5 (rs 1296954), (3) Grade 3+ neutropenia with CLHNI, 1hRET, SLC22A2 (rs 316019), CYP4F2 (rs2074900) (4) ORR with ALDH2 (rs 886205), MTHFR (rs 1801133). (5) PFS with T1/2-HNI, XDH (rs 207440), and ABCB11 (rs 4148777). CONCLUSIONS: Exploratory associations were observed between Irinotecan PK/PD with hepatic functional imaging and extensive pharmacogenomics. Further work is required to confirm and validate these findings in a larger cohort of patients. AUSTRALIAN NEW ZEALAND CLINICAL TRIALS REGISTRY (ANZCTR) NUMBER: ACTRN12610000897066, Date registered: 21/10/2010.
PURPOSE:Irinotecan (IR) displays significant PK/PD variability. This study evaluated functional hepatic imaging (HNI) and extensive pharmacogenomics (PGs) to explore associations with IR PK and PD (toxicity and response). METHODS: Eligible patients (pts) suitable for Irinotecan-based therapy. At baseline: (i) PGs: blood analyzed by the Affymetrix-DMET™-Plus-Array (1936 variants: 1931 single nucleotide polymorphisms [SNPs] and 5 copy number variants in 225 genes, including 47 phase I, 80 phase II enzymes, and membrane transporters) and Sanger sequencing (variants in HNF1A, Topo-1, XRCC1, PARP1, TDP, CDC45L, NKFB1, and MTHFR), (ii) HNI: pts given IV 250 MBq-99mTc-IDA, data derived for hepatic extraction/excretion parameters (CLHNI, T1/2-HNI, 1hRET, HEF, Td1/2). In cycle 1, blood was taken for IR analysis and PK parameters were derived by non-compartmental methods. Associations were evaluated between HNI and PGs, with IR PK, toxicity, objective response rate (ORR) and progression-free survival (PFS). RESULTS: N = 31 pts. The two most significant associations between PK and PD with gene variants or HNI parameters (P < 0.05) included: (1) PK: SN38-Metabolic Ratio with CLHNI, 1hRET, (2) Grade 3+ diarrhea with SLC22A2 (rs 316019), GSTM5 (rs 1296954), (3) Grade 3+ neutropenia with CLHNI, 1hRET, SLC22A2 (rs 316019), CYP4F2 (rs2074900) (4) ORR with ALDH2 (rs 886205), MTHFR (rs 1801133). (5) PFS with T1/2-HNI, XDH (rs 207440), and ABCB11 (rs 4148777). CONCLUSIONS: Exploratory associations were observed between Irinotecan PK/PD with hepatic functional imaging and extensive pharmacogenomics. Further work is required to confirm and validate these findings in a larger cohort of patients. AUSTRALIAN NEW ZEALAND CLINICAL TRIALS REGISTRY (ANZCTR) NUMBER: ACTRN12610000897066, Date registered: 21/10/2010.
Authors: Michael Michael; Mick Thompson; Rod J Hicks; Paul L Mitchell; Andrew Ellis; Alvin D Milner; Julia Di Iulio; Andrew M Scott; Volker Gurtler; Janelle M Hoskins; Stephen J Clarke; Niall C Tebbut; Kian Foo; Michael Jefford; John R Zalcberg Journal: J Clin Oncol Date: 2006-08-08 Impact factor: 44.544
Authors: R H Mathijssen; R J van Alphen; J Verweij; W J Loos; K Nooter; G Stoter; A Sparreboom Journal: Clin Cancer Res Date: 2001-08 Impact factor: 12.531
Authors: Ron H J Mathijssen; Jaap Verweij; Maja J A de Jonge; Kees Nooter; Gerrit Stoter; Alex Sparreboom Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: X Y Chu; Y Kato; K Ueda; H Suzuki; K Niinuma; C A Tyson; V Weizer; J E Dabbs; R Froehlich; C E Green; Y Sugiyama Journal: Cancer Res Date: 1998-11-15 Impact factor: 12.701
Authors: Jessica M van der Bol; Ron H J Mathijssen; Walter J Loos; Lena E Friberg; Ron H N van Schaik; Maja J A de Jonge; André S Th Planting; Jaap Verweij; Alex Sparreboom; Floris A de Jong Journal: J Clin Oncol Date: 2007-06-11 Impact factor: 44.544
Authors: Yosuke Horita; Y Yamada; Y Hirashima; K Kato; T Nakajima; T Hamaguchi; Y Shimada Journal: Cancer Chemother Pharmacol Date: 2009-06-25 Impact factor: 3.333
Authors: Femke M de Man; Andrew K L Goey; Ron H N van Schaik; Ron H J Mathijssen; Sander Bins Journal: Clin Pharmacokinet Date: 2018-10 Impact factor: 6.447